Results 11 to 20 of about 259,590 (298)

Antiretroviral Therapy [PDF]

Infectious Disease Clinics of North America, 2014
In this article, the scientific evidence and professional guidelines regarding the timing of antiretroviral therapy initiation are reviewed, with discussion of the increasingly persuasive evidence in favor of starting treatment early in the course of human immunodeficiency virus disease.
Katya R. Calvo, Eric S. Daar
  +7 more sources

Treatment Initiation, Program Attrition and Patient Treatment Outcomes associated with Scale-up and Decentralization of HIV care in rural Malawi [PDF]

, 2012
To describe patient antiretroviral therapy (cART) outcomes associated with intensive decentralization of services in a rural HIV program in ...
McGuire, Megan, Pinoges, Loretxu, Kanapathipillai, Rupa, Munyenyembe, Tamika, Huckabee, Martha, Makombe, Simon, Szumilin, Elisabeth, Heinzelmann, Annette, Pujades-Rodríguez, Mar   +8 more
core   +18 more sources

Interleukin-2 therapy in patients with HIV infection [PDF]

, 2009
BACKGROUND Used in combination with antiretroviral therapy, subcutaneous recombinant interleukin-2 raises CD4+ cell counts more than does antiretroviral therapy alone. The clinical implication of these increases is not known.
Aagaard, B., Abrams, D., Angus, B., Aragon, E., Arnaiz, J., Babiker, A., Borup, L., Clotet, B., Collins, G., Cooper, D. A., Cordwell, B., Darbyshire, J., Dodds, W., Dragsted, U., Emery, S., Fau, A., Fleck, S., Fox, L., Gey, D., Gordin, F., Grarup, J., Grijsen, M., Hengge, U., Herrero, P., Jansson, P., Jensen, B., Jensen, K., Juncher, H., Lane, H. C., Lange, J., Langebeek, N., Lopez, P., Losso, M. H., Lundgren, J., Lundgren, J. D., Lévy, Y., Matthews, C., Mitsuyasu, R., Mollerup, D., Neaton, J. D., Pearson, M., Phillips, A., Reilev, S., Reiss, P., Routy, J. P., Tambussi, G., Tillmann, K., van der Horst, C., Varea, S., Wentworth, D.   +49 more
core   +13 more sources

Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières [PDF]

, 2008
OBJECTIVES: To describe the use of second-line protease-inhibitor regimens in Médecins Sans Frontières HIV programmes, and determine switch rates, clinical outcomes, and factors associated with survival.
Alexandra Calmy, Boyd, Braitstein, Calmy, Calmy, Chaiwarith, Colebunders, Daniel O'Brien, Ferradini, Gallant, Galárraga, Ivers, Laurent, Ledergerber, Mar Pujades-Rodríguez, Mocroft, Nicastri, Orrell, Pierre Humblet, Renaud-Théry, Srasuebkul, Sungkanuparph, Vasan, Vekemans, Walmsley   +24 more
core   +2 more sources

Outcomes of a remote, decentralized health center-based HIV/AIDS antiretroviral program in Zambia, 2003 to 2007 [PDF]

, 2009
A cross-sectional study of patients living with HIV/ AIDS treated during 2003 to 2007 in decentralized, rural health centers in Zambia was performed to measure virological outcomes after 12 months of antiretroviral therapy and identify factors associated
Elema, R, Mills, C, Yun, O, Lokuge, K, Ssonko, C, Nyirongo, N, Mtonga, V, Zulu, H, Tu, D, Verputten, M, O'Brien, D P   +10 more
core   +2 more sources

Weight gain at 3 months of antiretroviral therapy is strongly associated with survival: evidence from two developing countries [PDF]

, 2009
BACKGROUND: In developing countries, access to laboratory tests remains limited, and the use of simple tools such as weight to monitor HIV-infected patients treated with antiretroviral therapy should be evaluated.
Arnaud Fontanet, Bagchi, Bisson, Bonard, Bonnet, Calmy, Christine Genevier, Diggle, Elisabeth Szumilin, Erikstrup, Etard, Ferradini, Ferradini, Gilks, Harries, Ivers, Jerene, Laurent Ferradini, Madec, Malvy, Mar Pujades, Paton, Saghayam, San Lio, Severe, Shetty, Shikuma, Silva, Spacek, Stringer, Suna Balkan, Tang, Van Damme, Yoann Madec   +33 more
core   +3 more sources

Virologic failure and second-line antiretroviral therapy in children in South Africa--the IeDEA Southern Africa collaboration [PDF]

, 2011
Article approval pendingWith expanding pediatric antiretroviral therapy (ART) access, children will begin to experience treatment failure and require second-line therapy. We evaluated the probability and determinants of virologic failure and switching in
Boulle, Andrew, Davies, Mary-Ann, Egger, Matthias, Eley, Brian, Giddy, Janet, Keiser, Olivia, Moultrie, Harry, Rabie, Helena, Technau, Karl, Van Cutsem, Gilles, Wood, Robin   +10 more
core   +2 more sources

Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia. [PDF]

, 2007
OBJECTIVE: Increasing access to highly active antiretroviral therapy to reach all those in need in developing countries (scale up) is slowly expanding to HIV-positive children, but documented experience remains limited. We aimed to describe the clinical,
Akao, K, Ford, N, Gupta, J, Janssens, B, Nerrienet, E, Nouhin, J, Raleigh, B, Soeung, S, Te, V, Vun, M   +9 more
core   +2 more sources

Immediate Antiretroviral Therapy Decreases Mortality Among Patients With High CD4 Counts in China: A Nationwide, Retrospective Cohort Study. [PDF]

, 2017
BackgroundClinical trials have demonstrated that immediate initiation of antiretroviral therapy (ART) reduces AIDS-related morbidity and mortality. We tested the hypothesis that initiating ART ≤30 days after human immunodeficiency virus (HIV) diagnosis ...
Brookmeyer, Ron, Detels, Roger, Dou, Zhihui, Li, Aihua, Ma, Ye, McGoogan, Jennifer M, Montaner, Julio SG, Qin, Qianqian, Shi, Cynthia X, Wu, Zunyou, Zhao, Yan   +10 more
core   +1 more source

Development and validation of a composite programmatic assessment tool for HIV therapy. [PDF]

PLoS ONE, 2012
We developed and validated a new and simple metric, the Programmatic Compliance Score (PCS), based on the IAS-USA antiretroviral therapy management guidelines for HIV-infected adults, as a predictor of all-cause mortality, at a program-wide level.
Viviane D Lima, Adrian Le, Bohdan Nosyk, Rolando Barrios, Benita Yip, Robert S Hogg, P Richard Harrigan, Julio S G Montaner   +7 more
doaj   +1 more source